Market Overview

Novartis Reports Evidence Gilenya Reduce MS Relapse Rates More Effectively than Interferons or Glatiramer Acetate


Novartis (NYSE: NVS) announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya® (fingolimod) in reducing risks of relapses compared to standard therapies[1]-[3]. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark.  Relapses

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (NVS)

View Comments and Join the Discussion!